- Open Access
Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
- Thys van der Molen1,
- Dirkje S. Postma2,
- Richard J. Martin3,
- Ron M. C. Herings4,
- Jetty A. Overbeek4,
- Victoria Thomas5,
- Cristiana Miglio5,
- Richard Dekhuijzen6,
- Nicolas Roche7,
- Theresa Guilbert8,
- Elliot Israel9,
- Wim van Aalderen10,
- Elizabeth V. Hillyer5,
- Simon van Rysewyk11 and
- David B. Price11, 12Email author
© The Author(s). 2016
- Received: 20 May 2016
- Accepted: 19 July 2016
- Published: 23 July 2016
The original article was published in BMC Pulmonary Medicine 2016 16:80
The original version of this article  unfortunately contained errors that have since been corrected.
The word “pharmo” has been fully capitalised to “PHARMO” throughout the article.
The reference to Table 2 in the first and second sentence under the Outcomes heading has been replaced with Fig. 3.
Under the Abbreviations heading ‘extrafine-particle’ was repeated, this has been corrected to ‘EF-HFA-BDP [Qvar®]: extrafine-particle hydrofluoroalkane beclomethasone dipropionate’.
The competing interests of Nicolas Roche and Theresa Guibert have been amended.
Academic affiliations for Dirkje S. Postma (2), Richard J. Martin (3), Ron M.C. Herrings (4), Jetty Overbeek (4), and Nicolas Roche (7) have been corrected.
Figure 3 in the online and pdf version did not match, this been amended.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.